413 related articles for article (PubMed ID: 16625863)
1. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.
Oberg K
Expert Rev Anticancer Ther; 2009 May; 9(5):557-66. PubMed ID: 19445573
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic and diagnostic implications of the somatostatin system in gastroenteropancreatic neuroendocrine tumour disease.
Höcker M; Wiedenmann B
Ital J Gastroenterol Hepatol; 1999 Oct; 31 Suppl 2():S139-42. PubMed ID: 10604118
[TBL] [Abstract][Full Text] [Related]
6. The management of gastroenteropancreatic neuroendocrine tumors with somatostatin analogues.
Khagi S; Saif MW
JOP; 2014 Jul; 15(4):295-8. PubMed ID: 25076324
[TBL] [Abstract][Full Text] [Related]
7. The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Grozinsky-Glasberg S; Grossman AB; Korbonits M
Mol Cell Endocrinol; 2008 May; 286(1-2):238-50. PubMed ID: 18037561
[TBL] [Abstract][Full Text] [Related]
8. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin Analogs in Clinical Practice: a Review.
Gomes-Porras M; Cárdenas-Salas J; Álvarez-Escolá C
Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32121432
[TBL] [Abstract][Full Text] [Related]
10. The antiproliferative effect of somatostatin analogs: clinical relevance in patients with neuroendocrine gastro-entero-pancreatic tumours.
Verslype C; Carton S; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Peeters M; Roeyen G; Van Hootegem P; Van Laethem JL; Van Cutsem E
Acta Gastroenterol Belg; 2009; 72(1):54-8. PubMed ID: 19402373
[TBL] [Abstract][Full Text] [Related]
11. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors.
Pokuri VK; Fong MK; Iyer R
Curr Oncol Rep; 2016 Jan; 18(1):7. PubMed ID: 26743514
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic neuroendocrine tumors: hormonal treatment updates.
Khagi S; Saif MW
JOP; 2014 Mar; 15(2):135-7. PubMed ID: 24618437
[TBL] [Abstract][Full Text] [Related]
13. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
14. Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors.
Pivonello R; Ferone D; Filippella M; Faggiano A; De Martino MC; Auriemma RS; Rota F; Lombardi G; Colao A
J Endocrinol Invest; 2003; 26(8 Suppl):82-8. PubMed ID: 15233220
[No Abstract] [Full Text] [Related]
15. Budget Impact of Somatostatin Analogs (SSAs) as Treatment for Metastatic Gastroenteropancreatic Neuroendocrine Tumors (mGEP-NETs) in US Hospitals.
Clin Adv Hematol Oncol; 2016 May; 14(5 Suppl 7):10-1. PubMed ID: 27168105
[No Abstract] [Full Text] [Related]
16. Clinical utility of lanreotide Autogel
Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs for the treatment of neuroendocrine tumors.
Culler MD; Oberg K; Arnold R; Krenning EP; Sevilla I; Díaz JA
Cancer Metastasis Rev; 2011 Mar; 30 Suppl 1():9-17. PubMed ID: 21369878
[TBL] [Abstract][Full Text] [Related]
18. Function and expression of somatostatin receptors of the endocrine pancreas.
Strowski MZ; Blake AD
Mol Cell Endocrinol; 2008 May; 286(1-2):169-79. PubMed ID: 18375050
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor subtypes in human non-functioning neuroendocrine tumors and effects of somatostatin analogue SOM230 on cell proliferation in cell line NCI-H727.
Ono K; Suzuki T; Miki Y; Taniyama Y; Nakamura Y; Noda Y; Watanabe M; Sasano H
Anticancer Res; 2007; 27(4B):2231-9. PubMed ID: 17695508
[TBL] [Abstract][Full Text] [Related]
20. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours.
Modlin IM; Pavel M; Kidd M; Gustafsson BI
Aliment Pharmacol Ther; 2010 Jan; 31(2):169-88. PubMed ID: 19845567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
